Based on the analysis of ProKidney Corp's profitability, liquidity, and operating efficiency, ProKidney Corp may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, ProKidney Corp's Other Stockholder Equity is quite stable compared to the past year. Total Liabilities is expected to rise to about 41.4 M this year, although the value of Total Stockholder Equity is projected to rise to (945.2 M). Key indicators impacting ProKidney Corp's financial strength include:
The essential information of the day-to-day investment outlook for ProKidney Corp includes many different criteria found on its balance sheet. An individual investor should monitor ProKidney Corp's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in ProKidney Corp.
ProKidney Corp competes with Relay Therapeutics, Stoke Therapeutics, Pliant Therapeutics, Black Diamond, and Arvinas. ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina. Prokidney Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining ProKidney Corp's current stock value. Our valuation model uses many indicators to compare ProKidney Corp value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ProKidney Corp competition to find correlations between indicators driving ProKidney Corp's intrinsic value. More Info.
ProKidney Corp is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, ProKidney Corp's Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value ProKidney Corp by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
ProKidney Corp Systematic Risk
ProKidney Corp's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. ProKidney Corp volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on ProKidney Corp correlated with the market. If Beta is less than 0 ProKidney Corp generally moves in the opposite direction as compared to the market. If ProKidney Corp Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one ProKidney Corp is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of ProKidney Corp is generally in the same direction as the market. If Beta > 1 ProKidney Corp moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in ProKidney Corp Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ProKidney Corp's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of ProKidney Corp growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of ProKidney Corp help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of ProKidney Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of ProKidney Corp based on widely used predictive technical indicators. In general, we focus on analyzing ProKidney Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build ProKidney Corp's daily price indicators and compare them against related drivers.
When determining whether ProKidney Corp is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if ProKidney Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Prokidney Corp Stock. Highlighted below are key reports to facilitate an investment decision about Prokidney Corp Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProKidney Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
For more information on how to buy ProKidney Stock please use our How to buy in ProKidney Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProKidney Corp. If investors know ProKidney will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProKidney Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.62)
Revenue Per Share
0.001
Return On Assets
(0.26)
Return On Equity
(0.41)
The market value of ProKidney Corp is measured differently than its book value, which is the value of ProKidney that is recorded on the company's balance sheet. Investors also form their own opinion of ProKidney Corp's value that differs from its market value or its book value, called intrinsic value, which is ProKidney Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProKidney Corp's market value can be influenced by many factors that don't directly affect ProKidney Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProKidney Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if ProKidney Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProKidney Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.